Opportunity Overview
The Flinn Foundation is accepting applications for the 2027 Bioscience Entrepreneurship Program, a year-long commercialization and investment-readiness program for Arizona-based early-stage bioscience companies. Up to six selected startups receive non-dilutive funding administered through the Arizona Bioindustry Association, together with structured advisorship, learning sessions, investor-readiness support and a final investment-style pitch opportunity.
Funding and Deadline
Each selected company receives $75,000 in non-dilutive funding support. With up to six companies selected, the announced cohort funding represents up to $450,000 in awards. Applications are due October 30, 2026 at 5:00 p.m. The official application page does not state a time zone, so applicants should confirm the portal clock before the deadline.
Eligibility
Applicants must be Arizona-based bioscience companies incorporated as an S-Corp, LLC or C-Corp and engaged in commercialization of bioscience research or biotechnology. Eligible areas include medical devices and equipment, diagnostics, health-focused technology platforms or delivery processes, therapeutics and pharmaceuticals, bio-agriculture, and related bioscience commercialization. The program defines early stage as pre-seed or seed companies with under $1,000,000 in raised dilutive funds or revenue. Research-only projects are not eligible.
Application Requirements
First-round screening requires the application form, a required 15-slide leave-behind pitch deck, and at least one letter of recommendation. Applicants may submit a second recommendation letter and an optional three-minute investor video pitch. Invited finalists present an in-person pitch to a judging panel.
Atlas Strategic Analysis
Atlas Opportunity Score: 78/100. This is credible, non-dilutive Arizona bioscience commercialization funding with a clearly defined application process and meaningful advisory support, but it is narrowly limited to very early-stage Arizona companies rather than healthcare delivery organizations.
N9+ Fit Score: 10/100. Medical devices and health-focused technology platforms are explicitly eligible, but this program funds the applicant company’s own commercialization trajectory; it is not a general equipment-purchase or healthcare-delivery grant. N9+ should not be inserted into an unrelated applicant’s proposal. A material N9+ role would require an eligible Arizona company to be legitimately commercializing the applicable technology or delivery model.
Direct-vendor review: Current rules require the applying company itself to be based in Arizona and meet the early-stage financial threshold. A non-Arizona-based vendor does not qualify as the direct applicant. No mandatory match or cost share is stated on the official program page.
Next Action
Eligible Arizona bioscience startups should confirm the early-stage financial threshold, assemble the required pitch deck and recommendation letter, and submit through the Flinn Foundation application portal by October 30, 2026 at 5:00 p.m. The Foundation also lists an information session on September 14 at noon and additional office-hour opportunities before the deadline.
Source Verification
Atlas verified this opportunity against the Flinn Foundation’s official Bioscience Entrepreneurship Program application and program pages on September 10, 2026. Applicants should use the current Flinn Foundation application portal and any subsequent program updates as the controlling source.